Skip to main content

CRS | CERES Regulatory Services

The Empaveli Resubmission Journey: From FDA CRL to Approval 

The Balversa Resubmission Journey: From FDA CRL to Approval

Hello Regulatory Scientists,  Today, let’s explore the journey of Empaveli (pegcetacoplan) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today.  Regulatory History and Initial Submission  Drug: Empaveli (pegcetacoplan) Mechanism of Action: Complement inhibitor that binds to complement protein […]

The Eliquis Resubmission Journey: Navigating the Path to FDA Approval

Hello Regulatory Scientists, Today, let’s explore the journey of Eliquis (apixaban) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Eliquis (apixaban) Mechanism of Action: Factor Xa inhibitor, which helps to […]